Duopharma hits record 1Q profit, surges 68% on strong sales and API price normalisation
written by
4
(TMRgraphic)
Duopharma Biotech Bhd’s net profit jumped 67.8% year-on-year to a record RM25.64 million for the quarter ended March 31, 2025 (1Q25), driven by strong sales across all segments and lower active pharmaceutical ingredient (API) costs.
Revenue rose 36.2% to RM262.74 million, bolstered by a surge in insulin sales to fulfil backlogged orders.
No dividend was declared for the quarter.
The group remains optimistic about the domestic outlook but is closely monitoring global risks such as US tariff policies.
It has contracts to supply RM684.15 million worth of products until end-2026. —TMR
The post Duopharma hits record 1Q profit, surges 68% on strong sales and API price normalisation appeared first on The Malaysian Reserve.
